story of the week
Outcomes of Tucatinib Combination Treatment After Trastuzumab Deruxtecan Therapy in Patients With ERBB2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer
JAMA Netw Open 2024 Apr 01;7(4)e244435, JS Frenel, J Zeghondy, C Guérin-Charbonnel, A Mailliez, E Volant, F Poumeaud, A Patsouris, M Arnedos, C Bailleux, J Cabal, L Galland, A de Nonneville, S Guiu, F Dalenc, B Pistilli, T Bachelot, JY Pierga, F Le Du, F Bocquet, L Larrouquere, D LoiratFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.